Variable | AMAN | AIDP | Unclassified |
---|---|---|---|
Age (years) | 48.4±20.2 | 47.7±18.7 | 41.6±16.8 |
Gender (male:female) | 21:19* | 53:20 | 40:31 |
Antecedent infection (%) | |||
Upper respiratory tract | 28 | 29 | 32 |
Gastrointestinal | 52 | 41 | 47 |
Others | 5 | 4 | 8 |
None | 15 | 26 | 13 |
Cranial nerve symptoms (%) | |||
Ophthalmoplegia | 15 | 12 | 17 |
Facial nerve palsy | 18 | 36 | 31 |
Oropharyngeal palsy | 10* | 22 | 31 |
Overall | 30* | 51 | 54 |
Sensory disturbance (%) | 53* | 74 | 59 |
Deep sensory disturbance (%) | 18 | 23 | 21 |
GBS disability score | |||
At nadir (% of the number of patients more than grade 3 or more) | 65 | 71 | 63 |
118 of 184 patients were analysed | |||
At 6 month after onset (% of the number of patients more than grade three or more) | 21 | 11 | 12 |
Antiganglioside antibody (%) | 174 of 184 patients were analysed | ||
GM1-positive | 54* | 14* | 27 |
GQ1b-positive | 9 | 11 | 16 |
*p<0.05 AMAN versus AIDP.
AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; GBS, Guillain-Barré syndrome.